Abstract
Cicatricial alopecias (CAs) are a disfiguring and difficult to treat types of hair disorder that are associated with distressing scalp symptoms and significant secondary morbidity, marked psychological impact, and significant loss of quality of life. The purpose of our study was to generate a proof-of-principle for a fundamentally innovative strategy for treating CAs by therapeutically targeting caveolin-1 (Cav1), which is the principal structural component of specialized membrane microdomains, using cholesterol depleting agents (cyclodextrins), in full length human ex vivo human hair follicle (HF) organ culture and in vivo mouse models.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
